Suchergebnisse - "Yau, Thomas"

PubPharm (287)

1

A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

enthalten in: JHEP reports : innovation in hepatology | 2024

von Santoro, A. | Assenat, E. | Yau, T. | +12

2

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : final results of a randomised phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2024

von Yau, T. | Kaseb, A. | Cheng, A. | +19

3

Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors : A first-in-human, dose-escalation, and dose-expansion study

enthalten in: Cancer | 2024

von Bishnoi, S. | Kotasek, D. | Aghmesheh, M. | +14

4

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Sangro, B. | Chan, S. | Kelley, R. | +123

5

Multimodal Integrative Genomics and Pathology Analyses in Neoadjuvant Nivolumab Treatment for Intermediate and Locally Advanced Hepatocellular Carcinoma

enthalten in: Liver cancer | 2024

von Cheung, T. | Wai-Hung Ho, D. | Lyu, S. | +12

6

Adverse events associated with the delivery of telerehabilitation : A scoping review protocol

enthalten in: PloS one | 2024

von Yau, T. | McIntyre, M. | Chan, J. | +7

7

Plain language summary of the HIMALAYA study : tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)

enthalten in: Future oncology (London, England) | 2023

von Abou-Alfa, G. | Lau, G. | Kudo, M. | +27

8

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors

enthalten in: Journal for immunotherapy of cancer | 2023

von Bauer, T. | Santoro, A. | Lin, C. | +16

9

Family-Specific Training Improves Linear B Cell Epitope Prediction for Emerging Viruses

enthalten in: IEEE/ACM transactions on computational biology and bioinformatics | 2023

von Liu, R. | Hu, Y. | Du, J. | +4

10

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Qin, S. | Chen, M. | Cheng, A. | +122

CommentIn: Lancet. 2023 Nov 18;402(10415):1806-1807. - PMID 37883983

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]